Trial reportPloS one2016
Treatment of Oral Biofilms by a D-Enantiomeric Peptide.
Trial report in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 1 synthesis or guideline pooled it, 58 citations in OpenAlex.
- How short peptides interact with oral cells? A systematic review.BMC oral health · 2025Pooled it
- An innate defense regulator peptide modulates the inflamed pulp microenvironment and promotes pulp repair.Bioactive materials · 2026Article
- Cytocompatibility of calcium hydroxide medicament combined with cationic peptide - AnJournal of conservative dentistry and endodontics · 2026Article
- Bioactive peptides in Endodontic infections: The Good, The Bad, and The Ugly.Probiotics and antimicrobial proteins · 2026Review
- Probiotics, Prebiotics, Synbiotics, Postbiotics, and Bioactive Agents in Modulating Harmful Oral Biofilms.Probiotics and antimicrobial proteins · 2026Review
- Evaluation of antimicrobial and antibiofilm efficacy of different antimicrobial peptides on multispecies biofilm of endodontic pathogens.Journal of conservative dentistry and endodontics · 2025Article
- Synthetic peptides targeting a mast cell-specific G protein-coupled receptor MRGPRB2 display anti-infective potential.Cell biomaterials · 2025Article
- Development of Synthetic Antimicrobial Peptides Based on Genomic Analysis of Streptococcus salivarius.Journal of clinical laboratory analysis · 2025Article
- Evaluation of bacterial biofilm, smear layer, and debris removal efficacy of a hydro-dynamic cavitation system with physiological saline using a new ex vivo model: a CLSM and SEM study.BMC oral health · 2025Article
- Article
- Constructing two bifunctional tooth-targeting antimicrobial peptides for caries management: an in vitro study.Clinical oral investigations · 2024Article
- Editorial: Antimicrobial peptides and their druggability, bio-safety, stability, and resistance.Frontiers in microbiology · 2024Article
- Article
- Effects of DJK-5 and chlorhexidine on exopolysaccharide volume and pH in oral biofilms.BMC oral health · 2023Article
- Peptides in Dentistry: A Scoping Review.Bioengineering (Basel, Switzerland) · 2023Article
- Antibiofilm and immunomodulatory resorbable nanofibrous filing for dental pulp regenerative procedures.Bioactive materials · 2022Article
- Antimicrobial and Antibiofilm Properties of Bioceramic Materials in Endodontics.Materials (Basel, Switzerland) · 2021Review
- Antibiofilm activity of host defence peptides: complexity provides opportunities.Nature reviews. Microbiology · 2021Review
- Effects of brief sodium fluoride treatments on the growth of early and mature cariogenic biofilms.Scientific reports · 2021Article
- Recent Advances in the Development of Antimicrobial and Antifouling Biocompatible Materials for Dental Applications.Materials (Basel, Switzerland) · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 2 countries.
Funding
Abstract
Almost all dental diseases are caused by biofilms that consist of multispecies communities. DJK-5, which is a short D-enantiomeric, protease-resistant peptide with broad-spectrum anti-biofilm activity, was tested for its effect on oral multispecies biofilms. Peptide DJK-5 at 10 μg/mL effectively prevented the growth of these microbes in culture media in a time-dependent manner. In addition to the prevention of growth, peptide DJK-5 completely killed both Streptococcus mutans and Enterococcus faecalis suspended from biofilms after 30 minutes of incubation in liquid culture media. DJK-5 also led to the effective killing of microbes in plaque biofilm. The proportion of bacterial cells killed by 10 μg/mL of DJK-5 was similar after 1 and 3 days, both exceeding 85%. DJK-5 was able to significantly prevent biofilm formation over 3 days (P = 0.000). After 72 hours of exposure, DJK-5 significantly reduced and almost completely prevented plaque biofilm production by more than 90% of biovolume compared to untreated controls (P = 0.000). The proportion of dead biofilm bacteria at the 10 μg/mL DJK-5 concentration was similar for 1- and 3-day-old biofilms, whereby >86% of the bacteria were killed. DJK-5 was also able to kill >79% and >85% of bacteria, respectively, after one-time and three brief treatments of 3-day-old biofilms. The combination of DJK-5 and chlorhexidine showed the best bacterial killing among all treatments, with ~83% and >88% of bacterial cells killed after 1 and 3 minutes, respectively. No significant difference was found in the percentage of biofilm killing amongst three donor plaque samples after DJK-5 treatment. In particular, DJK-5 showed strong performance in inhibiting biofilm development and eradicating pre-formed oral biofilms compared to L-enantiomeric peptide 1018. DJK-5 was very effective against oral biofilms when used alone or combined with chlorhexidine, and may be a promising agent for use in oral anti-biofilm strategies in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.